(XERS) Xeris Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.041m USD | Total Return: 23.8% in 12m

Stock Endocrine Therapies, Neurological Therapies, Glucagon, Levothyroxine
Total Rating 32
Safety 29
Buy Signal -0.61
Biotechnology +0.2
Pharmaceuticals -0.1
Market Cap: 1,041m
Avg Trading Vol: 11.2M USD
ATR: 5.45%
Peers RS (IBD): 36.1
Risk 5d forecast
Volatility64.1%
Rel. Tail Risk-17.7%
Reward TTM
Sharpe Ratio0.33
Alpha-20.45
Character TTM
Beta1.425
Beta Downside1.784
Drawdowns 3y
Max DD50.67%
CAGR/Max DD0.88
EPS (Earnings per Share) EPS (Earnings per Share) of XERS over the last years for every Quarter: "2021-03": -0.3, "2021-06": -0.41, "2021-09": -0.39, "2021-12": -0.42, "2022-03": -0.25, "2022-06": -0.19, "2022-09": -0.16, "2022-12": -0.1, "2023-03": -0.12, "2023-06": -0.14, "2023-09": -0.09, "2023-12": -0.1, "2024-03": -0.14, "2024-06": -0.1, "2024-09": -0.11, "2024-12": -0.03, "2025-03": -0.06, "2025-06": -0.01, "2025-09": 0.0035, "2025-12": 0.06, "2026-03": 0,
EPS CAGR: 122.30%
EPS Trend: 89.1%
Last SUE: -0.59
Qual. Beats: 0
Revenue Revenue of XERS over the last years for every Quarter: 2021-03: 8.195, 2021-06: 8.906, 2021-09: 11.035, 2021-12: 21.669, 2022-03: 22.073, 2022-06: 25.306, 2022-09: 29.725, 2022-12: 33.144, 2023-03: 33.196, 2023-06: 38.008, 2023-09: 48.32, 2023-12: 44.39, 2024-03: 40.638, 2024-06: 48.065, 2024-09: 54.268, 2024-12: 60.099, 2025-03: 60.119, 2025-06: 71.539, 2025-09: 74.38, 2025-12: 85.807, 2026-03: null,
Rev. CAGR: 43.63%
Rev. Trend: 97.7%
Last SUE: -0.07
Qual. Beats: 0
Risks
Technicals: choppy
Description: XERS Xeris Pharmaceuticals

Xeris Biopharma Holdings, Inc. (XERS) is a commercial-stage biopharmaceutical company. It focuses on developing and commercializing treatments for chronic endocrine and neurological conditions.

The companys product portfolio includes Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for Cushings syndrome. Xeris also has XP-8121, a hypothyroidism treatment, in Phase 3 clinical trials. Biopharmaceutical companies typically invest heavily in research and development, with long lead times for product approval.

Xeris operates in the Pharmaceuticals sub-industry, a sector characterized by high regulatory hurdles and patent protection for novel drugs.

For more detailed financial and operational analysis, consider exploring ValueRays comprehensive reports.

Headlines to Watch Out For
  • Gvoke sales growth drives revenue expansion
  • Keveyis and Recorlev market penetration crucial for profitability
  • XP-8121 clinical trial success impacts future valuation
  • Regulatory approval risks affect new product launches
Piotroski VR‑10 (Strict) 6.0
Net Income: 554k TTM > 0 and > 6% of Revenue
FCF/TA: 0.10 > 0.02 and ΔFCF/TA 21.57 > 1.0
NWC/Revenue: 44.80% < 20% (prev 33.10%; Δ 11.70% < -1%)
CFO/TA 0.07 > 3% & CFO 28.6m > Net Income 554k
Net Debt (-73.3m) to EBITDA (35.0m): -2.09 < 3
Current Ratio: 2.19 > 1.5 & < 3
Outstanding Shares: last quarter (180.1m) vs 12m ago 20.78% < -2%
Gross Margin: 81.70% > 18% (prev 0.81%; Δ 8.09k% > 0.5%)
Asset Turnover: 82.61% > 50% (prev 62.86%; Δ 19.75% > 0%)
Interest Coverage Ratio: 0.77 > 6 (EBITDA TTM 35.0m / Interest Expense TTM 29.1m)
Altman Z'' -4.95
A: 0.34 (Total Current Assets 240.3m - Total Current Liabilities 109.6m) / Total Assets 383.5m
B: -1.75 (Retained Earnings -671.3m / Total Assets 383.5m)
C: 0.06 (EBIT TTM 22.5m / Avg Total Assets 353.3m)
D: -1.82 (Book Value of Equity -671.3m / Total Liabilities 369.8m)
Altman-Z'' Score: -4.95 = D
Beneish M -3.04
DSRI: 0.88 (Receivables 51.0m/40.4m, Revenue 291.8m/203.1m)
GMI: 0.99 (GM 81.70% / 80.53%)
AQI: 0.77 (AQ_t 0.30 / AQ_t-1 0.39)
SGI: 1.44 (Revenue 291.8m / 203.1m)
TATA: -0.07 (NI 554k - CFO 28.6m) / TA 383.5m)
Beneish M-Score: -3.04 (Cap -4..+1) = AA
What is the price of XERS shares? As of April 05, 2026, the stock is trading at USD 5.80 with a total of 1,986,314 shares traded.
Over the past week, the price has changed by +11.85%, over one month by +1.68%, over three months by -14.81% and over the past year by +23.77%.
Is XERS a buy, sell or hold? Xeris Pharmaceuticals has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy XERS.
  • StrongBuy: 4
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the XERS price?
Wallstreet Target Price 11.1 92.1%
Analysts Target Price 11.1 92.1%
XERS Fundamental Data Overview as of 03 April 2026
P/E Forward = 77.5194
P/S = 3.5686
P/B = 73.0588
Revenue TTM = 291.8m USD
EBIT TTM = 22.5m USD
EBITDA TTM = 35.0m USD
Long Term Debt = 220.3m USD (from longTermDebt, last quarter)
Short Term Debt = 6.23m USD (from shortTermDebt, last quarter)
Debt = 37.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -73.3m USD (from netDebt column, last quarter)
Enterprise Value = 968.2m USD (1.04b + Debt 37.8m - CCE 111.0m)
Interest Coverage Ratio = 0.77 (Ebit TTM 22.5m / Interest Expense TTM 29.1m)
EV/FCF = 25.63x (Enterprise Value 968.2m / FCF TTM 37.8m)
FCF Yield = 3.90% (FCF TTM 37.8m / Enterprise Value 968.2m)
FCF Margin = 12.94% (FCF TTM 37.8m / Revenue TTM 291.8m)
Net Margin = 0.19% (Net Income TTM 554k / Revenue TTM 291.8m)
Gross Margin = 81.70% ((Revenue TTM 291.8m - Cost of Revenue TTM 53.4m) / Revenue TTM)
Gross Margin QoQ = 77.77% (prev 85.22%)
Tobins Q-Ratio = 2.52 (Enterprise Value 968.2m / Total Assets 383.5m)
Interest Expense / Debt = 18.94% (Interest Expense 7.15m / Debt 37.8m)
Taxrate = 0.0% (0.0 / 11.1m)
NOPAT = 22.5m (EBIT 22.5m * (1 - 0.00%))
Current Ratio = 2.19 (Total Current Assets 240.3m / Total Current Liabilities 109.6m)
Debt / Equity = 2.76 (Debt 37.8m / totalStockholderEquity, last quarter 13.7m)
Debt / EBITDA = -2.09 (Net Debt -73.3m / EBITDA 35.0m)
Debt / FCF = -1.94 (Net Debt -73.3m / FCF TTM 37.8m)
Total Stockholder Equity = -10.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.16% (Net Income 554k / Total Assets 383.5m)
 RoE = -5.33% (negative equity) (Net Income TTM 554k / Total Stockholder Equity -10.4m)
 RoCE = 10.71% (EBIT 22.5m / Capital Employed (Equity -10.4m + L.T.Debt 220.3m))
RoIC = 10.62% (NOPAT 22.5m / Invested Capital 211.6m)
WACC = 11.28% (E(1.04b)/V(1.08b) * Re(11.0%) + D(37.8m)/V(1.08b) * Rd(18.94%) * (1-Tc(0.0)))
Discount Rate = 11.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.18%
[DCF] Terminal Value 57.41% ; FCFF base≈37.8m ; Y1≈24.8m ; Y5≈11.3m
[DCF] Fair Price = 1.26 (EV 144.1m - Net Debt -73.3m = Equity 217.3m / Shares 172.4m; r=11.28% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 89.07 | EPS CAGR: 122.3% | SUE: -0.59 | # QB: 0
Revenue Correlation: 97.72 | Revenue CAGR: 43.63% | SUE: -0.07 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.01 | Chg7d=+0.004 | Chg30d=-0.059 | Revisions Net=-2 | Analysts=4
EPS current Year (2026-12-31): EPS=0.14 | Chg7d=+0.019 | Chg30d=-0.172 | Revisions Net=-2 | Growth EPS=+0.0% | Growth Revenue=+31.6%
EPS next Year (2027-12-31): EPS=0.37 | Chg7d=+0.001 | Chg30d=-0.119 | Revisions Net=-1 | Growth EPS=+160.5% | Growth Revenue=+23.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle